IP Library Granted Patent US 12,357,843
Granted Patent B2
US 12,357,843 · App. 17/972,557 · Granted Jul 15, 2025

Methods of skin treatment with laser light

Inventors: Michael A. Karavitis (San Pedro, CA); Amogh Kothare (Fremont, CA)
Assignee: Cutera, Inc.
A61N5/067A61N5/0616A61N2005/007A61N2005/0659
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,357,843
App. No.
17/972,557
Granted
Jul 15, 2025
Kind
B2
Abstract

Dermatological systems and methods for reducing pain associated with treating of skin with high-fluence therapeutic laser light including applying a first agent to solubilize oils, removing the first agent and oil to reduce the level of oil in the skin by at least 85%, rehydrating the skin after the oil removal, applying a contact cooling element including a cooling window to the area within five minutes of rehydrating the skin, cooling the skin from a first to a second temperature, and applying at least one high-fluence therapeutic laser pulse to the skin.

Claims (37)

1. A method of reducing a level of pain perceived by a patient in response to a pain-inducing treatment of a target skin area with high-fluence therapeutic laser light, the target skin area comprising an epidermis layer and a target structure within a dermis layer, the method comprising:

a) applying to a stratum corneum of a first skin area of the patient a first agent adapted to solubilize oils secreted by the skin, the stratum corneum having a first level of skin oil associated therewith;

b) removing at least a portion of the first agent and the skin oil to reduce the first level of skin oil by at least 85%;

c) after said removing, applying an aqueous rehydrating solution to the first skin area to reduce entrapped air within the stratum corneum of the first skin area without applying oil to the stratum corneum;

d) applying a contact cooling element comprising a cooling window to the first skin area within a time interval of 5 minutes after applying the rehydrating solution to the first skin area, wherein the contact cooling window comprises a material that is transmissive to the high-fluence therapeutic laser light having a first wavelength at which the absorption coefficient of sebum exceeds the absorption coefficient of water, and cooling the first skin area from a first temperature to a second temperature, the first wavelength ranging from 1200 nm to 1800 nm; and

e) after cooling the first skin area to the second temperature, applying at least one high-fluence therapeutic laser light pulse having the first wavelength through the cooling window to the target skin area within the first skin area, wherein steps (a)-(c) are adapted to reduce the absorption of therapeutic laser light pulse energy in the epidermis layer and increase the amount of therapeutic laser pulse energy reaching the target structure.

2. The method of claim 1 , wherein the first agent comprises one or more of an acetone solution and an alcohol solution.

3. The method of claim 1 , wherein said removing step comprises removing the skin oil sufficient to reduce the first level of skin oil by at least 90%.

4. The method of claim 1 , wherein said removing step comprises removing the oil sufficient to reduce the first level of skin oil by at least 95%.

5. The method of claim 1 , wherein the first skin area is an area to be treated for acne, and wherein applying the at least one high-fluence therapeutic laser pulse having the first wavelength comprises applying a therapeutic laser pulse having a fluence of at least 15 J/cm 2 .

6. The method of claim 1 , applying the rehydrating solution comprises applying the rehydrating solution selected from water and an aqueous solution comprising one or more of a buffering agent, an acid, a medicine, an antibiotic, a cleansing agent, and an optical clarifying agent.

7. The method of claim 1 , further comprising: f) applying an optical clarifying agent to the target skin area within the first skin area; and g) waiting for a first time interval ranging from 1 minute to 60 minutes after applying the optical clarifying agent, to reduce optical scattering in the target skin area of the first skin area; wherein applying the at least one high-fluence therapeutic laser pulse to the target skin area occurs after the first time interval has elapsed.

8. The method of claim 7 , wherein the optical clarifying agent comprises dimethyl sulfoxide (DMSO).

9. The method of claim 1 , wherein applying the at least one high-fluence therapeutic laser pulse comprises applying one or more laser pulses having a fluence in the range of 5-40 J/cm2.

10. The method of claim 1 , wherein applying the at least one high-fluence therapeutic laser pulse comprises applying one or more laser pulses having a fluence in the range of 10-25 J/cm2.

11. The method of claim 1 , wherein applying the contact cooling element comprising the cooling window to the first skin area comprises applying the contact cooling window to the first skin area within a time interval of 2 minutes after applying the rehydrating solution.

12. The method of claim 1 , wherein applying the contact cooling element comprising the cooling window to the first skin area comprises applying the contact cooling window to the first skin area within a time interval of 1 minute after applying the rehydrating solution.

13. The method of claim 1 , wherein the step of applying the first agent comprises: 1) determining the first level of skin oil; and 2) applying the first agent to the stratum corneum after determining the first level of skin oil.

14. The method of claim 1 , wherein the step removing at least the portion of the first agent and the oil comprises: 1) removing at least the portion of the first agent and the skin oil; and 2) after the removing, determining a second level of skin oil.

15. The method of claim 14 , wherein the step of removing at least the portion of the first agent and the oil comprises: 3) repeating the steps of removing at least the portion of the first agent and the oil and determining the second level of skin oil until the first level of skin oil has been reduced by at least 85%.

16. The method of claim 1 , wherein the first agent comprises at least one organic agent capable of at least partially solubilizing the skin oil.

17. A method of treating the skin of a patient to reduce a level of pain associated with treating a target skin area with high-fluence therapeutic laser light, the target skin area comprising an epidermis layer and a target structure within a dermis layer, the method comprising:

a) applying to an epidermis of a first skin area of the patient an oil-removing agent, the epidermis of the first skin area having a first level of skin oil associated therewith;

b) removing at least a portion of the oil-removing agent and the skin oil sufficient to reduce the first level of skin oil in the epidermis of the first skin area by at least 85%;

c) after said removing, applying an aqueous rehydrating solution to the epidermis of the first skin area to reduce entrapped air within the epidermis of the first skin area without applying oil to the stratum corneum;

d) applying a contact cooling element comprising a cooling window to the first skin area within a time interval of 5 minutes after applying the rehydrating solution to the epidermis of the first skin area, wherein the contact cooling window comprises a material that is transmissive to the high-fluence therapeutic laser light having a first wavelength at which the absorption coefficient of sebum exceeds the absorption coefficient of water, and cooling the first skin area from a first temperature to a second temperature, the first wavelength ranging from 1200 nm to 1800 nm; and

e) after cooling the first skin area to the second temperature, applying at least one high-fluence therapeutic laser light pulse having the first wavelength through the cooling window to the target skin area within the first skin area, wherein steps (a)-(c) are adapted to reduce the absorption of therapeutic laser light pulse energy in the epidermis and increase the amount of therapeutic laser pulse energy reaching the target structure.

18. The method of claim 17 , wherein applying at least one high-fluence therapeutic laser pulse comprises applying one or more laser pulses having a fluence in the range of 8-28 J/cm2.

19. A method of treating the skin of a patient to reduce a level of pain associated with treating a target skin area with high-fluence therapeutic laser light, the target skin area comprising an epidermis layer and a dermis layer, the method comprising:

a) applying to a stratum corneum of a first skin area of the patient a first, aqueous agent to clean the skin, the stratum corneum having a first level of skin oil associated therewith;

b) removing at least a portion of the first agent and the oil to reduce the first level of skin oil to a second level of skin oil that is less than the first level of skin oil;

c) after said removing of the first, aqueous agent and oil, applying to the stratum corneum of the first skin area a second agent adapted to solubilize oils secreted by the skin;

d) removing at least a portion of the second agent and the skin oil to reduce the second level of skin oil to a third level of skin oil that is at least 85% less than the first level of skin oil;

e) after said removing of the second agent and the oil, applying an aqueous rehydrating solution to the first skin area to reduce entrapped air within the stratum corneum of the first skin area without applying oil to the stratum corneum;

f) applying a contact cooling element comprising a cooling window to the first skin area within a time interval of 5 minutes after applying the rehydrating solution to the first skin area, wherein the contact cooling window comprises a material that is transmissive to the high-fluence therapeutic laser light having a first wavelength at which the absorption coefficient of sebum exceeds the absorption coefficient of water, and cooling the first skin area from a first temperature to a second temperature the first wavelength ranging from 1200 nm to 1800 nm; and

g) after cooling the first skin area to the second temperature, applying at least one high-fluence therapeutic laser light pulse having the first wavelength through the cooling window to the target skin area within the first skin area, wherein steps (a)-(e) are adapted to reduce the absorption of therapeutic laser light pulse energy in the epidermis and increase the amount of therapeutic laser pulse energy reaching the target structure.

20. The method of claim 19 , wherein the level of pain perceived by the patient is less than a level of pain associated with not following the method of claim 19 .

Assignments (4)
SECURITY INTEREST Recorded May 5, 2025
From: CUTERA, INC.
To: WILMINGTON SAVINGS FUND SOCIETY, FSB
Reel/Frame 071019/0980 →
RELEASE OF SECURITY INTEREST Recorded May 5, 2025
From: WILMINGTON SAVINGS FUND SOCIETY, FSB
To: CUTERA, INC.
Reel/Frame 071020/0001 →
SECURITY INTEREST Recorded Mar 13, 2025
From: CUTERA, INC.
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS COLLATERAL AGENT
Reel/Frame 070505/0728 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 30, 2022
From: KARAVITIS, MICHAEL A.; KOTHARE, AMOGH
To: CUTERA, INC.
Reel/Frame 061587/0816 →
Continuity (2)
Provisional Application 63324017 · Mar 25, 2022
Related Publication 20230302295A1 · Sep 28, 2023
References Cited (49)
US 6419642B1 · Marchitto et al. · 2002 [cited by applicant]
US 6425873B1 · Marchitto et al. · 2002 [cited by applicant]
US 6524242B2 · Subramanyan · 2003 [cited by examiner]
US 6866659B2 · Nemati · 2005 [cited by applicant]
US 7118868B2 · Berlin · 2006 [cited by applicant]
US 7259109B2 · Meagley · 2007 [cited by applicant]
US 8323273B2 · Rylander et al. · 2012 [cited by applicant]
US 9105458B2 · Trimpin et al. · 2015 [cited by applicant]
US 9168388B2 · Rylander et al. · 2015 [cited by applicant]
US 9364287B2 · DeBenedictis et al. · 2016 [cited by applicant]
US 9615750B2 · Liopo et al. · 2017 [cited by applicant]
US 10369170B1 · Buck · 2019 [cited by applicant]
US 20010050083A1 · Marchitto et al. · 2001 [cited by applicant]
US 20040152080A1 · Berlin · 2004 [cited by applicant]
US 20050107399A1 · Boman et al. · 2005 [cited by applicant]
US 20050154382A1 · Altshuler · 2005 [cited by examiner]
US 20060003948A1 · Krasutsky et al. · 2006 [cited by applicant]
US 20060121489A1 · Gorenstein et al. · 2006 [cited by applicant]
US 20060267156A1 · Meagley · 2006 [cited by applicant]
US 20070207284A1 · McClintic · 2007 [cited by applicant]
US 20070299431A1 · Jakubowski et al. · 2007 [cited by applicant]
US 20080038376A1 · Giles · 2008 [cited by applicant]
US 20080097557A1 · Eggers et al. · 2008 [cited by applicant]
US 20080097559A1 · Eggers et al. · 2008 [cited by applicant]
US 20080215039A1 · Slatkine et al. · 2008 [cited by applicant]
US 20090053290A1 · Sand et al. · 2009 [cited by applicant]
US 20100261176A1 · Mitragotri et al. · 2010 [cited by applicant]
US 20110135571A1 · Lin et al. · 2011 [cited by applicant]
US 20110190745A1 · Uebelhoer et al. · 2011 [cited by applicant]
US 20120059307A1 · Harris et al. · 2012 [cited by applicant]
US 20130041308A1 · Hennings et al. · 2013 [cited by applicant]
US 20130306856A1 · Trimpin et al. · 2013 [cited by applicant]
US 20150196639A1 · Lando · 2015 [cited by examiner]
US 20160018361A1 · Trimpin et al. · 2016 [cited by applicant]
US 20160030726A1 · Hwang et al. · 2016 [cited by applicant]
US 20170165194A1 · Meng et al. · 2017 [cited by applicant]
US 20180236260A1 · Tagliaferri · 2018 [cited by examiner]
US 20190227032A1 · Trimpin et al. · 2019 [cited by applicant]
US 20200190158A1 · Eveleth et al. · 2020 [cited by applicant]
US 20200230081A1 · Pathak · 2020 [cited by applicant]
US 20200258729A1 · Karancsi et al. · 2020 [cited by applicant]
US 20200343084A1 · Trimpin et al. · 2020 [cited by applicant]
JP 2008531133 · 2008 [cited by examiner]
Vargas, Gracie et al., “Use of an Agent to Reduce Scattering in Skin,” in Lasers in Surgery and Medicine. [cited by applicant]
Vargas, Gracie et al., “Use of Hyperosmotic Chemical Agent to Improve the Laser Treatment of Cutaneous Vascular Lesions,” in Journal of Biomedical Optics, vol. 13, No. 2, 021114-1 to 02114-8, (Mar./Apr. 2008). [cited by applicant]
Mcnicols, Roger J. et al., “Temporary Dermal Scatter Reduction: Quantitative Assessment and Implications for Improved Laser Tattoo Removal,” in Lasers in Surgery and Medicine, vol. 36, 289-296 (2005). [cited by applicant]
Khan, Misbah H. et al., “Can Topically Applied Optical Clearing Agents Increase the Epidermal Damage Threshold and Enhance Therapeutic Safety,” in Lasers in Surgery and Medicine, vol. 35 No. 2, 93-95 (2004). [cited by applicant]
Hanslick, Jennifer L. et al., “Dimethyl Sulfoxide (DMSO) Produces Widespread Apoptosis in the Developing Central Nervous System,” in Neurobiology of Disease, vol. 34, 1-10 (2009). [cited by applicant]
Bui, Albert K. et al., “Revisiting Optical Clearing with Dimethyl Sulfoxide (DMSO),” in Lasers in Surgery and Medicine vol. 41, 142-148 (2009). [cited by applicant]